News & Events

HTG Molecular Announces Extension to Precision Diagnostic Partnership (PDP) Program Three for Companion Diagnostic Submission

TUCSON, Ariz., Sept. 27, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (“HTG”), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it has entered into an amendment to the third statement of work (“SOW Three”) under its Master Assay Development, Commercialization and Manufacturing Agreement with QIAGEN Manchester Limited (“QIAGEN”).

Full press release here

Posted on:

Return To List

Page last updated September 27, 2018